At present, T-DM1 is under investigation in 36 active phase I–III clinical trials registered on ClinicalTrials.gov in ErbB2-positive breast cancer, lung cancer, colorectal cancer and other solid tumors in various combinations. Here, ERBB2 is linked to breast cancer.